資源描述：
《肝衰竭預(yù)后研究與慢性乙型肝炎優(yōu)化治療療效評(píng)價(jià)》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫(kù)。
1、華中科技大學(xué)碩士學(xué)位論文肝炎患者在ALT復(fù)常、病毒學(xué)應(yīng)答方面有較好療效，但療效差別無(wú)統(tǒng)計(jì)學(xué)意義，而聯(lián)合用藥可減少耐藥的發(fā)生。本課題創(chuàng)新點(diǎn)及意義：綜合分析了湖北地區(qū)ALF病因構(gòu)成及預(yù)后因素，客觀評(píng)價(jià)了ALSS治療HBV-ACLF近期療效及預(yù)后生存，初步評(píng)估了核苷（酸）類(lèi)似物優(yōu)化治療療效。本研究可為今后臨床中的重型肝炎或肝衰竭及慢性乙型肝炎抗病毒治療提供借鑒。關(guān)鍵詞：肝衰竭；慢性乙型肝炎；預(yù)后；人工肝支持系統(tǒng)；優(yōu)化治療本研究受?chē)?guó)家傳染病科技重大專(zhuān)項(xiàng)（2008ZX10002-011）、國(guó)家重點(diǎn)基礎(chǔ)研究發(fā)展計(jì)劃（973計(jì)劃）（2005CB5
2、22901，2007CB512804，2009CB522500）、國(guó)家自然科學(xué)基金（30170889，30271170，30400412，30571646，30700701，81001313，81101248）、科技部國(guó)際科技合作計(jì)劃（2011DFA31030）、德中跨學(xué)科重大合作項(xiàng)目（TRR60）和中國(guó)博士后科學(xué)基金(20090460949)資助。4華中科技大學(xué)碩士學(xué)位論文Studiesonprognosisofpatientswithliverfailureandevaluationoftheefficacyofoptimize
3、dtreatmentforchronichepatitisB1,2Candidate:JianKang12Supervisor:Prof.Dong-liangYang,YueChen1TeachingandresearchdivisionofInfectiousDiseases,XieheHospitalofTongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan,China.2TeachingandresearchdivisionofInfectious
4、Diseases,TaiheHospitalofHubeiUniversityofMedicine,Shiyan,China.AbstractObjective1.ToreviewretrospectivelyconfertothenewstandardofALFetiologicfactorsandprognosisinpatientswithacuteliverfailure.2.Toinvestigateclinicalefficacy，theconsequencesofartificialliversupportsystem
5、treatmentandinfluencefactorsofprognosisinpatientswithHBVrelatedACLF.3.ToevaluatetheefficacyofOptimizedstrategyforHBeAg-positionchronichepatitisBpatientswithlamifudineresistancereceivingADVplusLAMorADVmonotherapy.Methods1.Atotalof61inALFpatientswereidentified.Thecauses，
6、laboratoryprofiles，prognosisinpatientswithacuteliverfailurewereinvestigated.2.Therewereatotalof56inHBV-ACLFpatientsintheresearch.Accordingtogenderandage.，therewere28patientswhoreceivedALSSinobservationgroupcases,28patientsincontrolgroup.Thelaboratoryprofilesandprognosi
7、sintwo5華中科技大學(xué)碩士學(xué)位論文groupswereinvestigated.3.79chronichepatitisBpatientswithLAMresistancewereramdomlyputinanobservationgrouporacontrolgroup.After24weeksoftreatment,serumHBVDNAlevelsweremeasuredandNormalizationofALT,drugresistancewerealsoconducted.Results1.Themostcommone
8、tiologyofALFinHubeiprovinceandneighboringregionswasHBVinducedin85.2%.BesidesALTandCr,therearesignificantdifferencesin
